News18» News»Business»AstraZeneca Shares Rise 4% on WHO's Emergency Use Approval of Covid-19 Vaccine
1-MIN READ

AstraZeneca Shares Rise 4% on WHO's Emergency Use Approval of Covid-19 Vaccine

Representative image.

Representative image.

The World Health Organization (WHO) on Monday listed AstraZeneca and Oxford University’s COVID-19 vaccine for emergency use, widening access to the relatively inexpensive shot in the developing world.

AstraZeneca share price rose on the Bombay Stock Exchange on Tuesday after the company received World Health Organization's (WHO) approval for emergency use of COVID-19 vaccines. Shares of AstraZeneca Pharma India rose 3.79 per cent to close at Rs 3769.10 on BSE. In the early trade on Tuesday, AstraZeneca Pharma share price added 11 per cent.

The World Health Organization (WHO) on Monday listed AstraZeneca and Oxford University’s COVID-19 vaccine for emergency use, widening access to the relatively inexpensive shot in the developing world.

“We now have all the pieces in place for the rapid distribution of vaccines. But we still need to scale up production,” Tedros Adhanom Ghebreyesus, WHO Director-General, told a news briefing.

“We continue to call for COVID-19 vaccine developers to submit their dossiers to WHO for review at the same time as they submit them to regulators in high-income countries,” he said.

A WHO statement said it had approved the vaccine as produced by AstraZeneca-SKBio (Republic of Korea) and the Serum Institute of India.

The listing by the UN health agency comes days after a WHO panel provided interim recommendations on the vaccine, saying two doses with an interval of around 8 to 12 weeks should be given to all adults, and can be used in countries with the South African variant of the coronavirus as well.

The WHO’s review found that the Astrazeneca vaccine met the “must-have” criteria for safety, and its efficacy benefits outweighed its risks.

The AstraZeneca/Oxford shot has been hailed because it is cheaper and easier to distribute than some rivals, including Pfizer/BioNTech’s, which was listed for emergency use by the WHO late in December.

Loading...